Related Experiment Video

Updated: May 13, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Aggressive statin therapy and the risk of malignancy

Joshua Liao1, John A Farmer

  • 1Department of Medicine, Brigham & Women's Hospital/Harvard Medical School, Boston, MA, USA. jmliao@partners.org

Current Atherosclerosis Reports
|February 26, 2013
PubMed

Insights

Statin therapy significantly reduces cardiovascular events. However, this review examines concerns and data regarding potential links between aggressive statin use and increased cancer risk.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Epidemiology

Background:

  • Pharmacologic agents inhibiting 3-hydroxy-3-methylglutaryl Co-A reductase (statins) advanced preventive medicine.
  • Clinical trials confirm statin therapy reduces cardiovascular events in primary and secondary prevention.
  • Early epidemiologic studies suggested an inverse cholesterol-mortality relationship, raising concerns about aggressive lipid lowering.

Purpose of the Study:

  • To evaluate epidemiologic and prospective trial data on the relationship between aggressive statin therapy and malignancy risk.
  • To address concerns regarding potential noncardiac mortality, including cancer, associated with intensive lipid-lowering strategies.

Main Methods:

  • Review of existing epidemiologic studies investigating cholesterol levels and mortality.
  • Analysis of meta-analyses from statin trials assessing cardiovascular outcomes and cancer risk.
  • Evaluation of prospective trial data examining the impact of aggressive statin therapy on malignancy.

Main Results:

  • Statin therapy is proven to reduce cardiovascular mortality.
  • Meta-analyses of statin trials indicated a potential, though debated, increase in cancer risk.
  • Epidemiologic data on cholesterol and mortality remain controversial regarding causality.

Conclusions:

  • While statins effectively prevent cardiovascular events, the potential association with increased cancer risk warrants continued investigation.
  • Further research is needed to clarify the complex relationship between aggressive lipid lowering and malignancy.
  • Balancing cardiovascular benefits against potential noncardiac risks remains a key consideration in statin therapy.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...